Get the Stockscreener App
4.59
3.15%
0.14
After Hours:
4.59
Myriad Genetics Inc stock is traded at $4.59, with a volume of 1.22M.
It is up +3.15% in the last 24 hours and down -6.71% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$4.45
Open:
$4.5
24h Volume:
1.22M
Relative Volume:
0.55
Market Cap:
$423.09M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-3.5308
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
-8.20%
1M Performance:
-6.71%
6M Performance:
-62.62%
1Y Performance:
-83.46%
1-Day Range:
$4.47
$4.6599
1-Week Range:
$4.425
$5.195
52-Week Range:
$3.8119
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.59 | 481.17M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Is Myriad Genetics Inc. a good long term investmentHigh-performance investment picks - jammulinksnews.com
Myriad Genetics Inc. Stock Analysis and ForecastExceptional profit velocity - jammulinksnews.com
What drives Myriad Genetics Inc. stock priceMarket-beating returns - jammulinksnews.com
What analysts say about Myriad Genetics Inc. stockTremendous growth potential - Autocar Professional
Insider Sellers Might Regret Selling Myriad Genetics Shares at a Lower Price Than Current Market Value - simplywall.st
Volatile Stocks to Avoid: Williams-Sonoma, Timken, and Myriad Genetics - AInvest
Evolent Health, West Pharmaceutical Services, Myriad Genetics, Tandem Diabetes, and Integra LifeSciences Shares Are Falling, What You Need To Know - Yahoo Finance
Trading (MYGN) With Integrated Risk Controls - news.stocktradersdaily.com
Myriad Genetics Earns 2025 Great Place To Work Certification™ - The Manila Times
Myriad Genetics Outperforms Average US Company by 30% in Workplace Excellence - Stock Titan
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know - MSN
Myriad Genetics (MYGN) Drops 3.85% Despite Expansion Efforts - AInvest
Parp Inhibitor Biomarkers Market Is Booming So Rapidly By 2032 | Myriad Genetics, Inc., F. Hoffmann-La Roche AG - openPR.com
Where are the Opportunities in (MYGN) - news.stocktradersdaily.com
5 Revealing Analyst Questions From Myriad Genetics’s Q1 Earnings Call - Yahoo Finance
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC - GlobeNewswire
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN
Myriad Genetics at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com Canada
Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
Consumer Genomics Market Is Booming So Rapidly 2025-2032 | Color - openPR.com
5-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
3 Reasons to Avoid MYGN and 1 Stock to Buy Instead - Yahoo Finance
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen - GlobeNewswire
7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow - ACCESS Newswire
Trend Tracker for (MYGN) - news.stocktradersdaily.com
US Direct-To-Consumer Genetic Testing Market Report 2025, - GlobeNewswire
US Direct-To-Consumer Genetic Testing Market Report 2025, Competitive Analysis of 23andMe, Gene by Gene, Ancestry, Genesis, EasyDNA, Veritas, Myriad Genetics, Taconic Biosciences, & Color Health - Yahoo Finance
Myriad Genetics (MYGN) Launches FirstGene Multiple Prenatal Screen | MYGN Stock News - GuruFocus
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.06%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):